Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia AAML 1331

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

Description:

For complete information, please view the study on clinicaltrials.gov

Medication Under Study:
Tretinoin and Arsenic Trioxide

Study Sponsor(s):

Children's Oncology Group; National Cancer Institute (NCI)

Full IRB Study Title:
AAML 1331, A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid: A COG Group wide Phase III Study

IRB Study ID:
150907

If you are interested in this study or have questions about your child's eligibility, please contact: Rebecca D. Considine Research Institute, 330-543-5012


Lead Principal Investigator:

Photo
Steven Kuerbitz, MD
Director, Divisional Research and Stem Cell Transplantation


Bookmark and Share

Developments Developments
Sign up for enewsletter
Get involved Get involved
Discover ways to support Akron Children's
    Contact Us

    330-543-5012

    E-mail

    find a location
    Find a location Type the first 3-5 letters of a specialty, service or location:
    Or, view: a map, a list of all locations, locations by city or locations near me.
    find a doctor
    Find a doctor Type the first 3-5 letters of the name, location or specialty:
    Or, view a list of all doctors by name, location and specialty.